Literature DB >> 19618187

[Myositides].

A Bornemann1, S Heitmann, A Lindner.   

Abstract

Idiopathic inflammatory myopathies (IIM) are diseases that are potentially amenable to immunomodulatory therapy. The challenge for the neuropathologist consists in distinguishing these myopathies from secondary inflammatory myopathies, especially in the context of some muscular dystrophies and metabolic diseases that may also show inflammatory infiltrates. There are generalized IIMs (dermatomyositis, polymyositis, sporadic inclusion body myositis) and focal ones (e.g., proliferative myositis, macrophagic myofasciitis). This review provides diagnostic criteria for each of these and includes pathogenetic mechanisms where available.

Entities:  

Mesh:

Year:  2009        PMID: 19618187     DOI: 10.1007/s00292-009-1167-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  25 in total

1.  Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies.

Authors:  K Amemiya; R P Granger; M C Dalakas
Journal:  Brain       Date:  2000-10       Impact factor: 13.501

2.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

3.  Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Authors:  Steven A Greenberg; Geraldine S Pinkus; Anthony A Amato; Jack L Pinkus
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

4.  Tubuloreticular structures in different types of myositis: implications for pathogenesis.

Authors:  Irene M Bronner; Jessica E Hoogendijk; Henk Veldman; Marja Ramkema; Marius A van den Bergh Weerman; Annemieke J M Rozemuller; Marianne de Visser
Journal:  Ultrastruct Pathol       Date:  2008 Jul-Aug       Impact factor: 1.094

5.  Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments.

Authors:  J R Mendell; Z Sahenk; T Gales; L Paul
Journal:  Arch Neurol       Date:  1991-12

6.  Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle.

Authors:  R K Gherardi; M Coquet; P Cherin; L Belec; P Moretto; P A Dreyfus; J F Pellissier; P Chariot; F J Authier
Journal:  Brain       Date:  2001-09       Impact factor: 13.501

7.  Inclusion body myositis: explanation for poor response to immunosuppressive therapy.

Authors:  R J Barohn; A A Amato; Z Sahenk; J T Kissel; J R Mendell
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

8.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

9.  Clinical correlates of granulomas in muscle.

Authors:  T Mozaffar; G Lopate; A Pestronk
Journal:  J Neurol       Date:  1998-08       Impact factor: 4.849

Review 10.  Developments in the scientific and clinical understanding of inflammatory myopathies.

Authors:  Ingrid E Lundberg; Cecilia Grundtman
Journal:  Arthritis Res Ther       Date:  2008-10-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.